Common Cancer Treatments Don’t Appear To Exacerbate Coronavirus Infection / I trattamenti antitumorali comuni non sembrano esacerbare l'infezione da coronavirus
Common Cancer Treatments Don’t Appear To Exacerbate Coronavirus Infection / I trattamenti antitumorali comuni non sembrano esacerbare l'infezione da coronavirus
Segnalato dal Dott. Giuseppe Cotellessa / Reported by Dr. Giuseppe Cotellessa
Background: The characterization of COVID-19 in patients with cancer remains limited in published studies and nationwide surveillance analyses. Reports from China and Italy have raised the possibility that patients with cancer on active therapy have a higher risk of COVID-19 related severe events, although there is a knowledge gap as to which aspects of cancer and its treatment increase the risk of severe COVID-19 disease.
A team of researchers at Memorial Sloan Kettering Cancer Center (MSK) reported on the epidemiology of COVID-19 illness experienced at an NCI-designated cancer center during the height of pandemic in New York City.
Bottom Line: According to a new study from Memorial Sloan Kettering published June 24 in Nature Medicine, patients in active cancer treatment who develop COVID-19 infection don't fare any worse than other hospitalized patients. Notably, metastatic disease, recent chemotherapy, or major surgery within the previous 30 days did not show a significant association with either hospitalization or severe respiratory illness due to COVID-19. Researchers say their findings suggest that no one should delay cancer treatment because of concerns about the virus.
Author Comments: "If you're an oncologist and you're trying to figure out whether to give patients chemotherapy, or if you're a patient who needs treatment, these findings should be very reassuring," says Ying Taur, MD, PhD, an Infectious Disease Specialist at MSK.
"The course and clinical spectrum of this disease is still not fully understood and this is just one of many studies that will need to be done on the connections between cancer and COVID-19," explained Mini Kamboj, MD, Chief Medical Epidemiologist, Infection Control at MSK. "But the big message now is clear: People shouldn't stop or postpone cancer treatment."
Method and Findings: The study looked at 423 MSK patients diagnosed with COVID-19 between March 10 and April 7. Overall, 40 percent were hospitalized for COVID-19, and 20 percent developed severe respiratory illness. About 9 percent had to be placed on a mechanical ventilator, and 12 percent died. The most frequent cancer types included solid tumors such as breast, colorectal, and lung cancer. Lymphoma was the most common hematologic malignancy. Over half of the cases were metastatic solid tumors.
Similar to other studies in the general population, the researchers found that age, race, cardiac disease, hypertension, and chronic kidney disease correlated with severe outcomes. The investigators found that patients taking immunotherapy drugs called immune checkpoint inhibitors were more likely to develop severe disease and require hospitalization. Further research is required to look at the effects of these drugs. But other cancer treatments, including chemotherapy and surgery, did not contribute to worse outcomes.
A team of researchers at Memorial Sloan Kettering Cancer Center (MSK) reported on the epidemiology of COVID-19 illness experienced at an NCI-designated cancer center during the height of pandemic in New York City.
Bottom Line: According to a new study from Memorial Sloan Kettering published June 24 in Nature Medicine, patients in active cancer treatment who develop COVID-19 infection don't fare any worse than other hospitalized patients. Notably, metastatic disease, recent chemotherapy, or major surgery within the previous 30 days did not show a significant association with either hospitalization or severe respiratory illness due to COVID-19. Researchers say their findings suggest that no one should delay cancer treatment because of concerns about the virus.
Author Comments: "If you're an oncologist and you're trying to figure out whether to give patients chemotherapy, or if you're a patient who needs treatment, these findings should be very reassuring," says Ying Taur, MD, PhD, an Infectious Disease Specialist at MSK.
"The course and clinical spectrum of this disease is still not fully understood and this is just one of many studies that will need to be done on the connections between cancer and COVID-19," explained Mini Kamboj, MD, Chief Medical Epidemiologist, Infection Control at MSK. "But the big message now is clear: People shouldn't stop or postpone cancer treatment."
Method and Findings: The study looked at 423 MSK patients diagnosed with COVID-19 between March 10 and April 7. Overall, 40 percent were hospitalized for COVID-19, and 20 percent developed severe respiratory illness. About 9 percent had to be placed on a mechanical ventilator, and 12 percent died. The most frequent cancer types included solid tumors such as breast, colorectal, and lung cancer. Lymphoma was the most common hematologic malignancy. Over half of the cases were metastatic solid tumors.
Similar to other studies in the general population, the researchers found that age, race, cardiac disease, hypertension, and chronic kidney disease correlated with severe outcomes. The investigators found that patients taking immunotherapy drugs called immune checkpoint inhibitors were more likely to develop severe disease and require hospitalization. Further research is required to look at the effects of these drugs. But other cancer treatments, including chemotherapy and surgery, did not contribute to worse outcomes.
ITALIANO
Contesto:
la caratterizzazione di COVID-19 nei pazienti con cancro rimane limitata negli studi pubblicati e nelle analisi di sorveglianza a livello nazionale. Rapporti dalla Cina e dall'Italia hanno sollevato la possibilità che i pazienti con cancro in terapia attiva abbiano un rischio più elevato di eventi gravi correlati a COVID-19, sebbene vi sia un divario di conoscenza su quali aspetti del cancro e il suo trattamento aumentano il rischio di gravi effetti della malattia di COVID- 19.
Un gruppo di ricercatori del Memorial Sloan Kettering Cancer Center (MSK) ha riferito sull'epidemiologia della malattia COVID-19 sperimentata in un centro oncologico designato dall'NCI durante l'intensità della pandemia a New York City.
Bottom Line:
Secondo un nuovo studio del Memorial Sloan Kettering pubblicato il 24 giugno su Nature Medicine, i pazienti in trattamento del cancro attivo che sviluppano l'infezione da COVID-19 non vanno peggio degli altri pazienti ricoverati in ospedale. In particolare, la malattia metastatica, la recente chemioterapia o la chirurgia maggiore nei 30 giorni precedenti non hanno mostrato un'associazione significativa con il ricovero o la malattia respiratoria grave a causa di COVID-19. I ricercatori affermano che i loro risultati suggeriscono che nessuno dovrebbe ritardare il trattamento del cancro a causa delle preoccupazioni sul virus.
Commenti dell'autore:
"Se sei un oncologo e stai cercando di capire se somministrare ai pazienti la chemioterapia o se sei un paziente che ha bisogno di cure, questi risultati dovrebbero essere molto rassicuranti", afferma Ying Taur, MD, PhD , specialista in malattie infettive presso MSK.
"Il decorso e lo spettro clinico di questa malattia non sono ancora del tutto chiari e questo è solo uno dei tanti studi che dovranno essere fatti sulle connessioni tra cancro e COVID-19", ha spiegato Mini Kamboj, MD, Chief Medical Epidemiologist, Infezione Controllo presso MSK. "Ma il grande messaggio ora è chiaro: le persone non dovrebbero interrompere o rimandare il trattamento del cancro."
Metodo e risultati:
lo studio ha esaminato 423 pazienti con MSK con diagnosi di COVID-19 tra il 10 marzo e il 7 aprile. Complessivamente, il 40% è stato ricoverato in ospedale per COVID-19 e il 20% ha sviluppato gravi malattie respiratorie. Circa il 9% ha dovuto essere posizionato su un ventilatore meccanico e il 12% è deceduto. I tipi di cancro più frequenti includevano tumori solidi come carcinoma mammario, colorettale e polmonare. Il linfoma era il tumore ematologico più comune. Oltre la metà dei casi erano tumori solidi metastatici.
Simile ad altri studi nella popolazione generale, i ricercatori hanno scoperto che età, razza, malattie cardiache, ipertensione e malattie renali croniche erano correlate a esiti gravi. I ricercatori hanno scoperto che i pazienti che assumevano farmaci per immunoterapia chiamati inibitori del checkpoint immunitario avevano maggiori probabilità di sviluppare malattie gravi e richiedere il ricovero in ospedale. Sono necessarie ulteriori ricerche per esaminare gli effetti di questi farmaci. Ma altri trattamenti contro il cancro, tra cui la chemioterapia e la chirurgia, non hanno contribuito a risultati peggiori.
Da:
Commenti
Posta un commento